When a dog is lost behind pain:
Find them with LIAVIUM™-CA1
LIAVIUM-CA1 (pregabalin chewable tablets) is the first and only FDA conditionally approved pregabalin for the management of pain and clinical signs associated with Chiari-like malformation (CM) and syringomyelia (SM) in dogs.
The missing piece in pain management
Pregabalin has long been the standard for managing neuropathic pain in humans. LIAVIUM-CA1 finally brings the proven science and relief to dogs.
Pregabalin dosed for dogs
|
30 mg
|
90 mg
|
180 mg
|
With a 6-7 hour elimination half life, LIAVIUM-CA1 is dosed only twice a day. This means there is less likelihood of breakthrough pain, and a potentially better therapeutic outcome.
Predictable
No compounding needed—FDA oversight ensures every dose meets quality standards.
Potent
High potency and rapid absorption work together to powerfully block pain signals.
Consistent
Twice-daily dosing maintains around-the-clock pain relief. No wearing off between doses—just steady comfort.
Pregabalin vs. Gabapentin
A review of human studies found that pregabalin provided faster and better relief of neuropathic pain than gabapentin, with fewer days of severe pain and fewer side effects.1
| Characteristic | Pregabalin | Gabapentin |
|---|---|---|
|
Approved formulation in dogs
|
Yes
|
No
|
|
Oral bioavailability
|
90% bioavailability
|
27–60% bioavailability
|
|
Absorption
|
Consistent and independent of dose and frequency
|
Variable — lower at higher doses
|
|
Mechanism of Action
|
Binds to α2δ subunit of voltage gated calcium channels
|
Binds to α2δ subunit of voltage gated calcium channels
|
|
Potency2
|
6–10x more potent
|
Less potent antinociceptive agent
|
|
Half-life2-4
|
6-7 hours
|
3-4 hours
|
|
Dosing
|
Twice daily
|
Three times daily
|
Stay informed
& ask questions
Sign up to stay updated with all things LIAVIUM-CA1 from launch dates to notice of full FDA approval. Plus, ask us anything in the question box and we’ll get back to soon with an answer from our team of experts.
Want to talk in person?
Let's connect.
|
ACVIM
6/11–6/13 Seattle, WA
Booth 621
|
AVMA
7/10–7/14 Anaheim, CA
Booth 1414
|
References
1Mayoral V, Galvez R, Ferrándiz M , Miguéns Vázquez X, Cordero-García C, Alcántara Montero A, Pérez C, Pérez-Páramo M. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Front Pain Res (Lausanne). 202 Jan 7;5:1513597.
2Dewey CW, Cerda-Gonzalez S, Levine JM, et al. Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. J Am Vet Med Assoc . 2009 Dec 15;235(12): 1442-9.
3Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010 Aug ;50(8): 941-50.
4Salazar V, Dewey C W, Schwark W, et al. Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. Vet Anaesth Analg. 2009 Nov; 36(6):574-80.